Chronicle Journal: Finance

Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Biomarin Pharmaceutical Ord Shs (NQ: BMRN)
126.81 USD  -1.92 (-1.49%)
Official Closing Price  /  Updated: 5:15 PM EDT, Jul 9, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 1,004,300
Open 129.00
Bid (Size) 126.00 (1)
Ask (Size) 132.00 (1)
Prev. Close 128.73
Today's Range 124.47 - 129.21
52wk Range 62.88 - 129.89
Shares Outstanding 176,713,314
Dividend Yield N/A
Performance
YTD
+50.89%
+50.89%
1 Month
+20.67%
+20.67%
3 Month
+59.41%
+59.41%
6 Month
+41.56%
+41.56%
1 Year
+49.00%
+49.00%
Top News
More News
BioMarin Promotes Company Veteran, Brian R. Mueller, to Executive Vice President, CFO
Andrea L. Acosta to be Promoted to Group Vice President, Chief Accounting Officer Read More
from PR Newswire
BioMarin to Participate in the Virtual BofA Securities 2020 Napa Biopharma Conference
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Henry Fuchs, M.D., President, Worldwide Research & Development and Brian Mueller, Acting Chief Financial Officer, will participate in... Read More
from PR Newswire
More News
Read More
BioMarin Provides Additional Data from Recent 4 Year Update of Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in Late-Breaking Oral Presentation at World Fe
from PR Newswire
uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of Directors
from GlobeNewswire News Releases
Strange: Bullish BMRN Analysts Actually See -1.6% Downside
category ETFs
from ETF Channel
Why This Stock List Is Smoking The S&P 500; How To Tell When To Sell
from Investor's Business Daily
Nasdaq 100 Movers: MAR, BMRN
category Stocks
from Market News Video
Biomarin Pharmaceutical Joins Elite Club Of Stocks With RS Ratings Over 90
from Investor's Business Daily
Pfizer's hemophilia gene therapy shows sustained effect in early-stage study
category companyNews
from Reuters: Company News
Pfizer and Sangamo's Gene Therapy Continues to Help Patients with Hemophilia in Clinical Trial
category Market News , SGMO , BMRN , and 1 more.
from Motley Fool
Nasdaq Beats Dow In Rangebound Trading; When To Buy These Restaurant Stocks
from Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]